News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Ind-Ra maintains a neutral outlook for healthcare in FY23
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Subscribe To Our Newsletter & Stay Updated
